AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices
ATRC•AtriCure’s third-quarter revenue rose 15% year over year to $154.50 million, beating the $151.22 million consensus, while adjusted EPS of $0.18 also topped expectations. The company forecast 2026 revenue of $606 million to $610 million and adjusted EPS of $0.40 to $0.46.
1. Quarterly results
AtriCure reported third-quarter revenue of $154.50 million, up 15% year over year and above analyst expectations of $151.22 million. Adjusted EPS was $0.18, compared with a consensus estimate of a $0.05 loss; adjusted EBITDA was $26.81 million versus an expected $19.62 million.
2. Outlook and sales drivers
The company forecasts full-year 2026 revenue of $606 million to $610 million, adjusted EBITDA of $91 million to $94 million, EPS of $0.21 to $0.27 and adjusted EPS of $0.40 to $0.46. U.S. growth was driven by pain management probes and appendage management devices, while minimally invasive ablation sales declined as fewer Hybrid procedures were performed amid physician adoption of PFA catheters. AtriCure attributed higher gross margin to favorable product and geographic mix.
